With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC

The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change at the FTC could lower M&A scrutiny.

Scroll to Top